This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Human medicines European public assessment report (EPAR): Exforge HCT, amlodipin...
Budesonide, prolonged release tablets, 9 mg product- specific bioequivalence gui...
A torrent of Trump administration policies is alarming scientists who fear the c...
The NIH, at a time of deep uncertainty, is losing its longtime No. 2 official, L...
Human medicines European public assessment report (EPAR): Dafiro HCT, amlodipine...
Biogen is continuing to thin its pipeline, dropping a phase 2 program acquired i...
In this tracker, Fierce Pharma is recording the regulatory progress of in-market...
A federal judge has issued a temporary pause across all states on the new NIH or...
Human medicines European public assessment report (EPAR): Exforge, amlodipine,va...
Human medicines European public assessment report (EPAR): Copalia, amlodipine,va...
Human medicines European public assessment report (EPAR): Dafiro, amlodipine,val...
A federal judge has issued a temporary pause across all states on the new NIH or...
Budesonide, gastro-resistant hard capsules, 3 mg, gastro- resistant granules, 9 ...
Want to stay on top of the science and politics driving biotech today? Sign up t...
Budesonide, gastro-resistant hard capsules with prolonged release properties, 3 ...
Want to stay on top of the science and politics driving biotech today? Sign up t...
A U.S. judge ordered federal agencies to restore access to health-related webpag...
Having kicked off the year with a T-cell engager deal, AbbVie has returned to th...
The company's HIV sales surged 16% during the quarter, setting the scene for its...
Get your daily dose of health and medicine every weekday with STAT’s free newsle...
Apple is launching a new study to investigate the relationships between differen...
Sanofi-backed Abcuro has secured $200 million in series C funds to power its ant...
Human medicines European public assessment report (EPAR): Piqray, alpelisib, Dat...